Bill Anderson gets Bayer AG CEO nod

Bill Anderson gets Bayer AG CEO nod

The supervisory board of Bayer AG has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the board of management on April 1, 2023.

Anderson was elected unanimously after a thorough selection process which began mid last year. Werner Baumann, current CEO of Bayer, will work closely with him on a smooth transition before retiring from Bayer after 35 years of service at the end of May 2023.

A chemical engineer by education, Anderson has served in various leadership positions in the life science industry over the past 25 years. Most recently, he served as CEO of Roche’s pharmaceuticals division, and before that, Anderson was CEO of Genentech, one of the pioneering companies in the biotech field.

Anderson has held several senior leadership positions in general management, product development and finance at Biogen, another innovation leader in the biotech sphere, and Raychem, an American technology and electronics company. During his time at Biogen, Genentech and Roche, Anderson was involved in the development and launch of 25 new medicines, including 15 blockbusters. In addition to his native country, the United States, Anderson has lived and worked in several European countries with postings in the United Kingdom, The Netherlands, Belgium and Switzerland. In his new role, he will be based in Leverkusen, Germany.

Anderson holds a Bachelor of Science in chemical engineering from the University of Texas, and Master of Science degrees in chemical engineering and management from the Massachusetts Institute of Technology (MIT).

Read the NOV/DEC 2022 issue of New AG International’s leading quarterly title, here.

Read the SEP/OCT 2022 issue of New AG International’s leading quarterly title, here.